As ImClone Investigation Continues, FDA Combines Drugs, Biologics Review; Memo Describes “Lengthy Process” That Led To FDA Decision; Oncology Community Praises FDA Move
ASCO, NCCS Call For Oncology Center
Zerhouni Appoints Two Institute Directors
ASCO: Anastrozole Adds Treatment Option, But Tamoxifen Remains Standard
NCI Program Develops Bioinformatics Tool To Design Cancer Drugs
Funding Opportunities
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field
- FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says - Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants
